Related Experiment Video

Updated: Sep 30, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.5K

Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies

Radoslav Janostiak1,2, Ariadna Torres-Sanchez1,2, Francesc Posas1,2

  • 1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.

Cancers
|March 10, 2022
PubMed

Insights

Retinoblastoma protein (Rb1), a key tumor suppressor, regulates cell cycle progression by inhibiting E2F transcription factors. Its complex post-translational modifications offer new avenues for cancer therapy design.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Retinoblastoma protein (Rb1) is a critical tumor suppressor, inhibiting cell cycle progression.
  • Rb1, along with p107 and p130, forms a protein family regulating cell proliferation.
  • Altered Rb1 expression or function is implicated in most human cancers.

Purpose of the Study:

  • To review recent advancements in Rb1 function and regulation.
  • To explore the complex post-translational modifications of Rb1.
  • To discuss potential novel cancer therapeutic strategies targeting Rb1.

Main Methods:

  • Literature review of recent research on Rb1.
  • Analysis of Rb1's role in cell cycle inhibition.
  • Examination of E2F transcription factor interactions and Rb1 phosphorylation.

Main Results:

  • Rb1 inhibits cell cycle progression primarily through binding and repressing E2F transcription factors.
  • Rb1 function is regulated by complex post-translational modifications, acting as a convergence point for multiple signaling pathways.
  • Downstream signaling effects of Rb1 can be both E2F-dependent and E2F-independent.

Conclusions:

  • Rb1's intricate regulation through post-translational modifications presents a complex but promising target for cancer therapy.
  • Understanding these regulatory mechanisms is crucial for developing effective treatments for Rb1-altered cancers.
  • Further research into Rb1's context-dependent signaling pathways may unlock new therapeutic avenues.
Keywords:
cancer therapiescell cycleretinoblastoma

More Related Videos

Reconstruct Human Retinoblastoma In Vitro06:52

Reconstruct Human Retinoblastoma In Vitro

Published on: October 11, 2022

1.5K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K